Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer.
A family history can be a valuable tool in the era of precision medicine. Although a few studies have described an association of family history of lung cancer with EGFR activating mutation, their impact on survival of lung cancer patients is unclear.The study included consecutive 829 non-small-cell...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5423629?pdf=render |
| _version_ | 1818288143980298240 |
|---|---|
| author | Jung Soo Kim Min Seong Cho Jong Hyeon Nam Hyun-Jung Kim Kyeng-Won Choi Jeong-Seon Ryu |
| author_facet | Jung Soo Kim Min Seong Cho Jong Hyeon Nam Hyun-Jung Kim Kyeng-Won Choi Jeong-Seon Ryu |
| author_sort | Jung Soo Kim |
| collection | DOAJ |
| description | A family history can be a valuable tool in the era of precision medicine. Although a few studies have described an association of family history of lung cancer with EGFR activating mutation, their impact on survival of lung cancer patients is unclear.The study included consecutive 829 non-small-cell lung cancer patients who received analysis of EGFR mutation in a prospective lung cancer cohort. Family history of lung cancer was obtained by face-to-face interviews at the time of diagnosis. An association of EGFR activating mutation with a family history of lung cancer in first-degree relatives was evaluated with multivariate logistic regression analysis, and its association with survival was estimated with Cox's proportional hazards model.Seventy five (9.0%) patients had family history of lung cancer. The EGFR mutation was commonly observed in patients with positive family history compared to those with no family history (46.7% v 31.3%, χ2 p = 0.007). The family history was significantly associated with the EGFR mutation (aOR and 95% CI: 2.01 and 1.18-3.60, p = 0.011). Patients with the positive family history survived longer compared to those without (MST, 17.9 v 13.0 months, log-rank p = 0.037). The presence of the EGFR mutation was associated with better survival in patients without the family history (aHR and 95% CI: 0.72 and 0.57-0.90, p = 0.005). However, this prognostic impact was not observed in patients with the positive family history (aHR and 95% CI: 1.01 and 0.50-2.36, p = 0.832).In comparison to patients without the family history, EGFR activating mutation was common, and it did not affect prognosis in patients with positive family history. |
| first_indexed | 2024-12-13T01:51:42Z |
| format | Article |
| id | doaj.art-0437e222e63941a592753b89fa38d1ae |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T01:51:42Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0437e222e63941a592753b89fa38d1ae2022-12-22T00:03:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01125e017701510.1371/journal.pone.0177015Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer.Jung Soo KimMin Seong ChoJong Hyeon NamHyun-Jung KimKyeng-Won ChoiJeong-Seon RyuA family history can be a valuable tool in the era of precision medicine. Although a few studies have described an association of family history of lung cancer with EGFR activating mutation, their impact on survival of lung cancer patients is unclear.The study included consecutive 829 non-small-cell lung cancer patients who received analysis of EGFR mutation in a prospective lung cancer cohort. Family history of lung cancer was obtained by face-to-face interviews at the time of diagnosis. An association of EGFR activating mutation with a family history of lung cancer in first-degree relatives was evaluated with multivariate logistic regression analysis, and its association with survival was estimated with Cox's proportional hazards model.Seventy five (9.0%) patients had family history of lung cancer. The EGFR mutation was commonly observed in patients with positive family history compared to those with no family history (46.7% v 31.3%, χ2 p = 0.007). The family history was significantly associated with the EGFR mutation (aOR and 95% CI: 2.01 and 1.18-3.60, p = 0.011). Patients with the positive family history survived longer compared to those without (MST, 17.9 v 13.0 months, log-rank p = 0.037). The presence of the EGFR mutation was associated with better survival in patients without the family history (aHR and 95% CI: 0.72 and 0.57-0.90, p = 0.005). However, this prognostic impact was not observed in patients with the positive family history (aHR and 95% CI: 1.01 and 0.50-2.36, p = 0.832).In comparison to patients without the family history, EGFR activating mutation was common, and it did not affect prognosis in patients with positive family history.http://europepmc.org/articles/PMC5423629?pdf=render |
| spellingShingle | Jung Soo Kim Min Seong Cho Jong Hyeon Nam Hyun-Jung Kim Kyeng-Won Choi Jeong-Seon Ryu Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer. PLoS ONE |
| title | Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer. |
| title_full | Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer. |
| title_fullStr | Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer. |
| title_full_unstemmed | Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer. |
| title_short | Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer. |
| title_sort | prognostic impact of egfr mutation in non small cell lung cancer patients with family history of lung cancer |
| url | http://europepmc.org/articles/PMC5423629?pdf=render |
| work_keys_str_mv | AT jungsookim prognosticimpactofegfrmutationinnonsmallcelllungcancerpatientswithfamilyhistoryoflungcancer AT minseongcho prognosticimpactofegfrmutationinnonsmallcelllungcancerpatientswithfamilyhistoryoflungcancer AT jonghyeonnam prognosticimpactofegfrmutationinnonsmallcelllungcancerpatientswithfamilyhistoryoflungcancer AT hyunjungkim prognosticimpactofegfrmutationinnonsmallcelllungcancerpatientswithfamilyhistoryoflungcancer AT kyengwonchoi prognosticimpactofegfrmutationinnonsmallcelllungcancerpatientswithfamilyhistoryoflungcancer AT jeongseonryu prognosticimpactofegfrmutationinnonsmallcelllungcancerpatientswithfamilyhistoryoflungcancer |